Genetic polymorphisms study of pharmacogenomic VIP variants in Han ethnic of China’s Shaanxi province

Pharmacogenomics, the study of the role of genetics in drug response, has recently become a focal point of research. Previous studies showed that genes associated with drug detoxification vary among different populations. However, pharmacogenomic information of the Zhuang ethnic group is scarce. The aim of the present study was to screen members of the Zhuang ethnicity in southwestern China for genotype frequencies of very important pharmacogenomic (VIP) variants and to determine the differences between the Zhuang ethnicity and other human populations.We genotyped 80 variants of VIP genes in 100 unrelated healthy Zhuang adults from the Yunnan province of China. Next, we analyzed the genotyping data with Structure and F-statistics (Fst).We compared our data with those of other populations using the HapMap data set, and observed that the frequency distribution of Zhuang population in Yunnan closely resembles that of JPT. Furthermore, population structure and Fst analysis showed that the Zhuang population is closely related to the Shaanxi Han population with respect to genetic background.Our study supplements existing information on Zhuang population pharmacogenomics and provides an extensive overview for developing personalized medicine.

show abstract

“…The same trend was observed in Zhuang people, suggesting that most Zhuang individuals may require lower dosage of warfarin. [ 10 , 14 ]…”

Section: Discussionmentioning

confidence: 99%

Genetic polymorphisms in very important pharmacogenomic variants in the Zhuang ethnic group of Southwestern China

Guo

Yan

et al. 2018

Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Average number of pair-wise differences, pair-wise F-statistics (Fst) were calculated in Arlequin v3.5.1.3 (Institute of Ecology and Evolution, University of Bern, Bern, Switzerland) with the genotype data of these 80 VIP variants. [ 18 , 19 ] Afterward, we used the MAGE6 software combining with the Fst values to draw out the evolutionary tree of Lisu and 11 HapMap populations.…”

Section: Methodsmentioning

confidence: 99%

“…Therefore, this present study was designed in order to provide information for personalized medicine by selecting and genotyping variants from the PharmGKB VIP database, which focused on published guidelines for dosage modification or drugs selection based on germ-line mutations in genes with pharmacokinetic or pharmacodynamic impact. [ 8 ] Specifically, we compared the genotype frequencies of VIP variants between the Lisu and other diverse populations based on HapMap database, and analyzed the genetic distance between Lisu and other ethnic groups in China including Miao, [ 9 ] Li, [ 10 ] Deng, [ 11 ] Sherpa, [ 12 ] Lhoba, [ 13 ] Tibetan, [ 14 ] Kyrhyz, [ 15 ] Tajik, [ 16 ] Mongol, [ 17 ] Shaanxi Han ethnic, [ 18 ] Uygur, [ 19 ] and 11 HapMap populations (Fig. 1 ).…”

Section: Introductionmentioning

confidence: 99%

Genetic polymorphisms of pharmacogenomic VIP variants in the Lisu population of southwestern China

Wang

Lei

et al. 2018

Medicine

Self Cite

View full text Add to dashboard Cite

Pharmacogenomic studies of different ethnic or racial groups have been used to develop personalized therapies specific to subjects. This study aimed to identify the distribution differences of very important pharmacogenetic (VIP) variants between the Lisu population from southwestern China and other ethnic groups.Eighty VIP variants in 37 genes were selected from the pharmacogenomic knowledge base (PharmGKB), and compared with genotype data of the Lisu population then compared with other 11 populations from the HapMap dataset and previously published data including Miao, Li, Deng, Sherpa, Lhoba, Tibetan, Kirghiz, Tajik, Mongol, Shaanxi Han ethnic, and Uygur populations.VDR rs1540339, MTHFR rs1801131, P2RY1 rs701265, and PTGS2 rs689466 were significantly different between Lisu and 11 HapMap populations. ANKK1 rs1800497 was the least statistical significant locus among selected single nucleotide polymorphisms. In addition, genetic background of Lisu was strongly closest to Shaanxi Han ethnic cohort, and followed by Chinese in metropolitan Denver population based on population structure and F-statistics analyses.Our results showed significant interethnic differences between Lisu and other populations, which will give useful information for prospective studies and better individualized treatments.

show abstract

“… 2 Single nucleotide polymorphism (SNP) is an important determinant of individual differences in drug therapy. Pharmacogenomics mainly involves knowledge of pharmacokinetic, pharmacodynamic and focuses on the inheritance of individual variation in the course of drug treatment, clarifies the influence of genomic variation on drug distribution and function, and provides guidance for individualised precise medical treatment 3 , 4 so on. The Pharmacogenomics Knowledge Base (PharmGKB: http://www.pharmgkb.org ) is a useful resource that aims to explain the gene-drug-disease relationship.…”

Section: Introductionmentioning

confidence: 99%

Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population

Peng

Xing

et al. 2021

PGPM

Self Cite

View full text Add to dashboard Cite

Background Genetic variation influences drug reaction or adverse prognosis. The purpose of this research was to genotype very important pharmacogenetic (VIP) variants in the Tibetan population. Methods and Materials Blood samples from 200 Tibetans were randomly collected and 59 VIP variants were genotyped, and then compared our data to 26 other populations in the 1000 project to further analyze and identify significant difference. Results The results showed that on comparing with most of the 26 populations from the 1000 project, rs4291 ( ACE ), rs1051296 ( SLC19A1 ) and rs1065852 ( CYP2D6 ) significantly differed in the Tibetan population. Furthermore, three significant loci were related to drug response. In addition, the allele frequency of Tibetans least differed from that of East Asian populations, and most differed from that of Americans. Conclusion Three significant loci of variation ACE rs4291, SLC19A1 rs1051296 and CYP2D6 rs1065852 were associated with drug response. This result will contribute to improving the information of the Tibetan in the pharmacogenomics database, and providing a theoretical basis for clinical individualised drug use in Tibetans.

show abstract

Genetic polymorphisms study of pharmacogenomic VIP variants in Han ethnic of China’s Shaanxi province

Cited by 8 publications

References 31 publications

Genetic polymorphisms in very important pharmacogenomic variants in the Zhuang ethnic group of Southwestern China

Genetic polymorphisms in very important pharmacogenomic variants in the Zhuang ethnic group of Southwestern China

Genetic polymorphisms of pharmacogenomic VIP variants in the Lisu population of southwestern China

Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population

Contact Info

Product

Resources

About